source
- Legend surges on early data for ‘in vivo’ lymphoma cell therapyInitial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.
- Bristol Myers Squibb assesses AI spending after deploying tools to thousands of staffBristol Myers Squibb has recently provided artificial intelligence applications to a large portion of its workforce. The company is now turning its attention to measuring the cost of these tools a…